Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) COO Sells $51,968.74 in Stock

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) COO Azmi Nabulsi sold 7,886 shares of Phathom Pharmaceuticals stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $6.59, for a total value of $51,968.74. Following the completion of the transaction, the chief operating officer now owns 233,390 shares of the company’s stock, valued at approximately $1,538,040.10. This trade represents a 3.27 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Azmi Nabulsi also recently made the following trade(s):

• On Thursday, December 19th, Azmi Nabulsi sold 1,118 shares of Phathom Pharmaceuticals stock. The shares were sold at an average price of $8.00, for a total value of $8,944.00.

Phathom Pharmaceuticals Stock Performance

PHAT opened at $6.90 on Friday. The business’s 50-day simple moving average is $8.00 and its 200-day simple moving average is $12.47. The company has a market cap of $471.80 million, a P/E ratio of -1.21 and a beta of 0.56. Phathom Pharmaceuticals, Inc. has a one year low of $6.07 and a one year high of $19.71.

Phathom Pharmaceuticals (NASDAQ:PHAT) last released its quarterly earnings data on Thursday, November 7th. The company reported ($1.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.57) by $0.25. The company had revenue of $16.35 million for the quarter, compared to analyst estimates of $12.54 million. During the same period in the previous year, the business posted ($0.76) EPS. As a group, analysts predict that Phathom Pharmaceuticals, Inc. will post -4.74 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on PHAT shares. Needham & Company LLC restated a “buy” rating and set a $28.00 target price on shares of Phathom Pharmaceuticals in a research note on Friday, January 10th. HC Wainwright reissued a “buy” rating and issued a $28.00 price objective on shares of Phathom Pharmaceuticals in a research report on Thursday, December 12th.

Institutional Investors Weigh In On Phathom Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of PHAT. Rhumbline Advisers grew its holdings in shares of Phathom Pharmaceuticals by 17.1% during the second quarter. Rhumbline Advisers now owns 55,178 shares of the company’s stock worth $568,000 after purchasing an additional 8,075 shares during the last quarter. Marshall Wace LLP purchased a new position in Phathom Pharmaceuticals during the 2nd quarter worth approximately $1,161,000. The Manufacturers Life Insurance Company increased its position in Phathom Pharmaceuticals by 10.6% during the second quarter. The Manufacturers Life Insurance Company now owns 13,941 shares of the company’s stock worth $144,000 after buying an additional 1,339 shares during the period. SG Americas Securities LLC purchased a new stake in Phathom Pharmaceuticals in the third quarter valued at approximately $244,000. Finally, Creative Planning boosted its holdings in shares of Phathom Pharmaceuticals by 25.7% in the third quarter. Creative Planning now owns 33,884 shares of the company’s stock valued at $613,000 after acquiring an additional 6,933 shares during the period. 99.01% of the stock is owned by hedge funds and other institutional investors.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.